Jubilant Pharmova Ltd 2024 SR
The report for FY 2023-24 highlights Jubilant Pharmova Limited's commitment to sustainability, achieving a 33% reduction in specific greenhouse gas emissions and a 16% decrease in specific water consumption compared to targets. The company attained a 93rd percentile in the S&P Global ESG Indices and a 'B' score from CDP for Climate Change and Water Security. It also increased employee training to 7.8 man-days per year. The report covers consolidated operations across its global pharmaceutical businesses, including Radiopharma and Allergy Immunotherapy.
Company: Jubilant Pharmova Ltd
Sector: Health Care
Country: India
Year: 2024
Type: SR
Pages: 33
Jubilant Pharmova Ltd
Business Responsibility And Sustainability Report
The report for FY 2023-24 highlights Jubilant Pharmova Limited's commitment to sustainability, achieving a 33% reduction in specific greenhouse gas emissions and a 16% decrease in specific water consumption compared to targets. The company attained a 93rd percentile in the S&P Global ESG Indices and a 'B' score from CDP for Climate Change and Water Security. It also increased employee training to 7.8 man-days per year. The report covers consolidated operations across its global pharmaceutical businesses, including Radiopharma and Allergy Immunotherapy.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2024
Published
Aug 8, 2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees